| Literature DB >> 27827927 |
Daniel F Markgraf1,2, Hadi Al-Hasani3,4, Stefan Lehr5,6.
Abstract
As a consequence of a sedentary lifestyle as well as changed nutritional behavior, today's societies are challenged by the rapid propagation of metabolic disorders. A common feature of diseases, such as obesity and type 2 diabetes (T2D), is the dysregulation of lipid metabolism. Our understanding of the mechanisms underlying these diseases is hampered by the complexity of lipid metabolic pathways on a cellular level. Furthermore, overall lipid homeostasis in higher eukaryotic organisms needs to be maintained by a highly regulated interplay between tissues, such as adipose tissue, liver and muscle. Unraveling pathological mechanisms underlying metabolic disorders therefore requires a diversified approach, integrating basic cellular research with clinical research, ultimately relying on the analytical power of mass spectrometry-based techniques. Here, we discuss recent progress in the development of lipidomics approaches to resolve the pathological mechanisms of metabolic diseases and to identify suitable biomarkers for clinical application. Due to its growing impact worldwide, we focus on T2D to highlight the key role of lipidomics in our current understanding of this disease, discuss remaining questions and suggest future strategies to address them.Entities:
Keywords: ceramide (CER); diabetes; diacylglycerol (DAG); lipid induced insulin resistance; lipid metabolism; lipidomics; metabolic disorder; type 2 diabetes
Mesh:
Substances:
Year: 2016 PMID: 27827927 PMCID: PMC5133841 DOI: 10.3390/ijms17111841
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Lipid classes and representative lipids. Classification according to LIPID MAPS® [1].
Figure 2(A) Representative image of human muscle (musculus vastus lateralis) biopsy sample. Biopsy was taken using a Bergstrom needle. White circle highlights aggregates of adipocytes; (B) analysis of cytosolic DAG concentration using LC-MS/MS. Human muscle biopsy sample with extramyocellular fat contamination was homogenized, fractionated and DAG in the cytosolic fraction were analyzed. A sample from the same biopsy, without any visible extramyocellular fat contamination was processed and analyzed the same way (Interassay variation coefficient of the applied LC-MS/MS method: maximum 4.8%, for the indicated DAG species); (C) schematic illustration of lipidomics workflow.
Figure 3Schematic illustration of scan modes used on triple quadrupole mass spectrometers. Q, Quadrupole; CID, collision induced dissociation.
Figure 4Schematic illustration of the relationship between obesity, ectopic accumulation of fat, insulin resistance and type 2 diabetes. Excessive metabolic energy is stored as TAGs in lipid droplets (LDs) in adipocytes. Extended exposure to high fat environment compromises storage capacity of adipocytes and leads to increased FA flux (upward arrows) and redirection of lipidstowards peripheral tissues, such as muscle and liver. Lipids exceeding the oxidative capacity of ectopic tissue are stored as TAG in LDs. Specific lipids trigger insulin resistance underlying type 2 diabetes. FA, Fatty acids.
Figure 5Lipid intermediates and their interactions with insulin signaling pathways in muscle. Free fatty acids (FFA) are transported into the cell, activated by acyl-CoA-synthase (ACS), and channeled into different pathways: (i) TAG synthesis occurs in four sequential reactions, catalyzed by members of the glycerol-3-phosphate-o-acyltransferase (GPAT), 1-acylglycerol-3-phosphate (AGPAT), phosphatidic acid phosphatase (PAP) and diacylglycerolacyl-transferase (DGAT) enzyme families in the ER and/or LDs. DAG, a key intermediate in TAG synthesis, can alternatively be generated by stimulus-dependent cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC) at the plasma membrane. The lipolysis of TAG by adipose triacylglycerol lipase (ATGL) generates DAG on LDs. Accumulated DAG species recruit and activate nPKCθ which leads to inhibitory phosphorylation of IRS1, downregulation of phosphatidylinositol-kinase 3 (PI3K), AKT and ultimately glucose uptake (indicated by downward arrows); (ii) FA-CoAs are converted to acylcarnitines (ACC) for shuttling and subsequent β-oxidation in mitochondria. Decreased or incomplete oxidation leads to their accumulation and affects insulin sensitivity; (iii) Ceramide synthesis is initiated by serine palmitoyl transferase (SPT) in the ER. Binding of saturated FA (SFA) to toll-like receptor 4 (TLR4) induces an inflammatory response, contributing to increased ceramide synthesis. Ceramides inhibit insulin signaling by decreasing the activity of AKT via protein phosphatase 2A (PP2A) or atypical PKCζ. Lysophosphatidic acid (LPA); Phosphatidic acid (PA); Diacylglycerol kinase (DGK); Inositol-1,4,5-Trisphosphate (IP3).
Lipid biomarker discovery in T2D and obesity.
| Reference | Volunteer | Sample | Increase | Decrease |
|---|---|---|---|---|
| [ | OIR vs. OIS | Serum | LacCer(22:0) SPM(18:1) SPM(24:1) | – |
| [ | Obese vs. lean (m/f) | Plasma | dCer(d18:0/22:0) TAG(16:0/18:1/18:1) DAG(18:0/20:4) | PC(32:0) PC(34:2) PC(36:2) lyso-alkyl-PC(24:2) lysoPE(16:0) acyl-alkyl-PC |
| OIR vs. OIS (m/f) | Plasma | DAG(14:1/16:0) CE(22:4) lyso-alkyl-PC(35:4) | Hex2-Cer(d18:1/22:0) Hex2-Cer(d18:1/24:0) lysoPC(22:0) | |
| [ | T2D vs. Ctr (m/f) | Plasma | CE(23:2) CE(23:3) CE(23:4) | PE(36:4) PE(36:5) PE(36:6) |
| [ | T2D vs. NGT | Plasma | dCer, Cer, PE, PI, PG, CE, DAG, TAG | acyl-alkyl-PC |
| Prediabetes vs. NGT | Plasma | dCer, Cer, PE, PI, PG, CE, DAG, TAG, free cholesterol | acyl-alkyl-PC | |
| [ | T2D prospective study, maximum 23.35 year follow-up (m/f) | Plasma | dCer(d18:0/18:0) lysoalkyl-PC(22:1) TAG(16:0/18:0/18:1) | – |
| [ | T2D prospective study, 7 year follow-up (m/f) | Serum | PC(32:1) PC(36:1) PC(38:3) PC(40:5) | SPM(16:1) lysoPC(18:2) acyl-alkyl-PC (34:3; 40:6; 42:5; 44:4; 44:5) |
| [ | T2D < 1 year diagnosis vs. Ctr (m/f) | Plasma | FFAs: (18:1w9, 18:4w3, 20:4w6, 22:4w6) ACC(C3) ACC(C4) ACC(18:2) | FFAs: (10:0; 13:0,; 14:1w5) SPM(16:1) SPM(OH)(14:1) PC(38:3) PC(44:3) PC(42:1) PC(42:2) lysoPC(28:1) |
| [ | T2D prospective study, 12 year follow-up (m/f) | Plasma | TAG (low carbon & double bond number) | TAG (high carbon & double bond number) |
OIR, Obese insulin resistant; OIS, Obese insulin sensitive; LacCer, Lactosylceramide; SPM, Sphingomyelin; Cer, Ceramide; dCer, Dihydroceramide; PC, Phosphatidylcholine; PE, Phosphatidylethanolamine; CE, Cholesterolester; Hex2-Cer Dihexosylceramide; FFA, free fatty acid; AAC, Acylcarnitine; PI, Phosphatidylinositol; PG, Phosphatidylglycerol; NGT, Normal glucose tolerant, m, male; f, female; Ctr, control.